Business Wire

Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

Share

Exscientia, a leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD).

AD is the most common form of dementia worldwide, with an estimated 44 million people living with AD or related form of dementia.1,2 Symptoms of this progressive disease are debilitating, distressing – for both those with the disease and their loved ones – and there is currently no cure.3

This exciting new partnership unites Exscientia's AI-driven molecular design capabilities with the deep therapy area knowledge and technical expertise of the ARUK-ODDI.

The collaboration will focus on a specific neuroinflammatory pathway implicated in the development of AD. Activation of the NLRP3 inflammasome has been shown to have an important role in AD pathogenesis and, while there have been other efforts to develop anti-inflammatory drugs for AD,4 targeting NLRP3 inflammasome inhibition in the brain is an innovative therapeutic approach.

Exscientia’s proven AI-driven technology will be applied to efficiently generate high-value novel clinical assets targeting this pathway. Feeding into this are chemical starting points that modulate NLRP3 inflammasome formation identified over years of research by the ARUK-ODDI. Coupling Exscientia's Centaur Chemist® AI-design systems with the ARUK-ODDI’s biology and screening expertise is expected to speed up delivery of distinct candidate molecules for AD.

Exscientia’s COO David Hallett commented: “Alzheimer’s is a dreadful disease that affects tens of millions worldwide. Despite clinical trials of numerous agents over a wide range of mechanisms, the last new Alzheimer’s medication, was approved nearly two decades ago. Alzheimer’s drug development is costly, complex and extremely challenging with clinical trial failure rate being the highest of any therapeutic area. Our mission is to make novel drugs available to all and we are excited to utilise our AI drug discovery platform and work alongside the expertise of the Alzheimer’s Research UK-Oxford Drug Discovery Institute team to accelerate innovation and develop potential medicines to solve this global epidemic.”

Expanding on this new relationship, Dr John Davis, CSO of the Alzheimer’s Research UK-Oxford Drug Discovery Institute drew attention to the benefits gained from the complementary capabilities of both partners: "We are delighted to be partnering with Exscientia. Their state-of-the-art AI capabilities will enable us to investigate multiple molecules in parallel and accelerate the project towards candidate declaration. Human genetic variation points towards a critical role for the body’s immune system in an individual’s risk of developing Alzheimer’s disease. It is vital that we develop treatments that target neuroinflammatory mechanisms underlying dementia.”

Dr Sara Imarisio, Head of Research at Alzheimer’s Research UK said:

“Scientist’s at our ARUK-Oxford Drug Discovery Institute are ideally placed to capitalise on the latest discoveries and work with partners to help translate this into drugs that could be tested in clinical trials. With nearly one million people in the UK living with dementia, there isn’t a moment to waste.”

ENDS

Notes to Editors:

About the NLRP3 inflammasome in the pathophysiology of Alzheimer’s disease (AD)

Inflammasomes are part of the innate immune system and are responsible for a wide range of inflammatory responses. In AD, activated NLRP3 inflammasome leads to the release of pro-inflammatory cytokine (IL-1 beta) and ASC (apoptosis-associated speck-like protein containing a caspase-recruitment domain) speck into the intercellular space. The release of ASC specks from microglia promotes amyloid-beta aggregation in AD. The accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together result in neurodegeneration and cognitive decline that characterize AD.

About Exscientia

Exscientia is an Artificial Intelligence (AI)-driven pharmatech, committed to discovering medicines in the fastest and most effective manner for patients. As a clinical stage company, Exscientia is the first to progress AI-designed small molecules into a clinical setting, demonstrating the ability of AI to transform the pharmaceutical industry.

Drug design is precision engineering at the molecular scale. To transform the industry, Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently re-apply enhanced knowledge through iterations of design. Because Exscientia’s AI systems learn more rapidly and effectively than human-led efforts, candidate molecules satisfying complex therapeutic requirements are discovered with revolutionary efficiency.

Exscientia puts AI at the centre of its strategy to revolutionise drug discovery, designing therapeutics for areas of high unmet need, that will positively impact patients.

About Centaur Chemist®

Centaur Chemist® is Exscientia’s solution to AI-driven drug design combining the latest AI-tech with the therapeutic experience of seasoned drug hunters. Driven by algorithms that mimic evolutionary design as well as deep learning to analyse complex information and active learning to extract insights from sparce, high-value datasets, Centaur Chemist® has been skilfully engineered to work with widest range of discovery data to ensure application to the widest range of discovery projects.

Centaur Biologist®

Centaur Biologist® supports the discovery and prioritisation of drug targets, ensuring that any candidate molecules developed will be aligned with key therapeutic objectives. With deep learning and vector embedding techniques Centaur Biologist® pinpoints trends and insights from big data and captures semantics that predict new unexpected associations.

For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI

About the ARUK-Oxford Drug Discovery Institute, University of Oxford

The Alzheimer’s Research UK Oxford Drug Discovery Institute is a drug discovery team, founded with funding from the charity Alzheimer’s Research UK, with the objective of accelerating the translation of basic science generated within universities towards therapeutic utility. The focus of the team is upon discovering treatments for the neurodegenerative diseases underlying dementia. Although Alzheimer’s disease is the most common cause of dementia and the charity bears its name, the remit of the ARUK-ODDI covers all diseases and mechanisms implicated in the different neurodegenerative diseases that contribute to dementia, including Alzheimer’s disease, Parkinson’s disease, vascular dementia and frontotemporal dementia. For more information, visit https://oxford-ddi.alzheimersresearchuk.org/about-the-institute/.

References:


1 World Health Organization. Fact Sheet. Dementia. Available at: https://www.who.int/news-room/fact-sheets/detail/dementia. Last accessed 10 February 2021

2 Alzheimer’s News Today. Available at: https://alzheimersnewstoday.com/alzheimers-disease-statistics/. Last accessed 10 February 2021

3 NHS. Alzheimer’s Disease. Available at: https://www.nhs.uk/conditions/alzheimers-disease/. Last accessed 10 February 2021

4 Immunity’s flipside: Microglia promote Alzheimer’s pathology during inflammation. Available at: https://www.novusbio.com/antibody-news/immunitys-flipside-microglia-promote-alzheimers-pathology-during-inflammation. Last accessed 10 February 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR Contacts:
For Exscientia
Mark Swindells, Chief Commercial Officer
contact@exscientia.ai

Anitra Sprauten, Edelman
anitra.sprauten@edelman.com
+44 (0)78 9685 9386

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Heise Medien relies on the Xpublisher editorial system18.5.2021 15:04:00 CEST | Press release

Heise Medien GmbH & Co. KG, one of Germany’s leading tech industry publishers, succeeded in establishing transparent and well-organized content and media asset management together with a highly streamlined production process for its magazines by implementing Xpublisher. Xpublisher supports content utilization along the entire value chain, from planning, editorial creation, editing, and layout to the final publication, based on a “content first” approach. This enables Heise Medien to publish across multiple channels in a way that is highly efficient, cost effective, and error free. "We are pleased that Heise Medien trusts in our expertise and successfully automates their magazine production with our editorial system", says Matthias Kraus, CEO of Xpublisher. The numbers are a testament to the project’s success: Instead of the typical production phase of ten days, the first issue of c't was ready for printing in just nine days. In digital production, the company succeeded in both enhancin

Trialbee Extends Executive Team and Launches Partner Program to Accelerate Growth, Expand Global Reach18.5.2021 15:00:00 CEST | Press release

Trialbee, a patient matching and enrollment platform, today announces key additions to its leadership team and a strategic partner program to further accelerate the company’s growth. These additions come during a period of unprecedented business results and will further scale the company’s global patient recruitment capabilities for clinical trials. Trialbee’s emergence as a trusted partner comes at a time when finding qualified patients and simplifying their journey into clinical research is more important than ever. Trialbee Hive™ utilizes real-world data (RWD) and advanced data science to model and expand patient targeting, providing greater awareness, inclusivity, and diversity of relevant patient populations. Interested patients are then engaged through Trialbee’s Candidate Manager platform that incorporates live nurse qualification and telehealth capabilities to refer study-ready patients into the trial, reducing site burden and enhancing enrollment outcomes. Four of the world’s

Styra Raises $40 Million in Series B Funding to Drive Access, Security and Compliance in Cloud-Native Applications18.5.2021 14:59:00 CEST | Press release

Styra, Inc., the founder of Open Policy Agent (OPA) and leader in cloud-native authorization, has raised a $40 million Series B funding round to continue driving the reinvention of policy and authorization for cloud-native applications. The round was led by Battery Ventures with participation from previous investors, A. Capital, Unusual Ventures, and Accel, as well as new investors at Capital One Ventures and Citi Ventures. With this funding, Dharmesh Thakker, General Partner at Battery Ventures, will be joining the Styra board. The round further solidifies its market leadership and provides capital to accelerate its founders’ vision—to create the standard for authorization—which started with OPA. OPA, initially proven out at scale by the likes of Netflix, Capital One, Atlassian, Pinterest and others, has now reached the point of over one million downloads per week. Styra has also seen exponential business traction in 2020, achieving 300% customer and commercial growth year-over-year,

Philip Morris International Reports Progress Toward Accelerating the End of Smoking18.5.2021 14:23:00 CEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today published its Integrated Report, a comprehensive overview of the company’s environmental, social, and governance (ESG) performance and its progress toward its purpose of delivering a smoke-free future. This includes its 2025 ambitions to have switched more than 40 million adult smokers to its smoke-free products, with half from non-OECD countries, and for smoke-free products to account for more than 50 percent of PMI’s total net revenues. Further accelerating PMI’s transformation, this year the company introduced two new 2025 ambitions, linked to its Business Transformation Metrics: for its smoke-free products to be available in 100 markets and for at least USD 1 billion in annual net revenues to come from “beyond nicotine” products. The Integrated Report also outlines case studies of early indications of PMI’s smoke-free products’ impacts in markets where such products have a meaningful presence. “I present this report with pride

CHRYSO Launches EnviroMix®, the First Global Range of Admixture Solutions and Services for Low-Carbon Concrete18.5.2021 14:00:00 CEST | Press release

CHRYSO, a leading player in the development of sustainable solutions in the construction industry, launches EnviroMix®, a global range of innovative products and services aimed at reducing and controlling the carbon footprint of concrete, dedicated to the ready-mix and precast concrete industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005573/en/ The development of low-carbon concrete, a major challenge for the construction industry. (Photo: Shutterstock) “The construction industry is accelerating its transformation to manage and reduce the environmental impact of its carbon footprint. CO2 footprint is a major challenge in the development of concrete formulations, coupled with the traditional properties of this material, and at the heart of our construction techniques (classes of strength and durability, workability, setting time, etc.)", states Frédéric Guimbal, Director of Concrete BU. In order to pick up the

Halliburton and TGS Collaborate to Advance Seismic Reservoir Monitoring18.5.2021 13:00:00 CEST | Press release

Halliburton Company (NYSE: HAL) and TGS-NOPEC Geophysical ASA (OSLO:TGS) today announced a collaboration to bring advanced seismic imaging to fiber optic sensing. The alliance will provide operators with advanced insight to determine their reservoir potential for oil and gas production or carbon storage. The Halliburton FiberVSP™ and Odassea™ distributed acoustic sensing solutions will now incorporate TGS’s seismic imaging workflows that process the entire seismic wavefield to generate high-resolution reservoir images. “We are excited to transform vertical seismic profiling to a full-field, digital, and intervention-less surveillance solution,” said Trey Clark, vice president of Wireline and Perforating. “Through our collaboration with TGS, we can now enable real-time monitoring of production across an entire field, allowing our customers to make better decisions and increase ultimate recovery.” “This solution enables enhanced reservoir understanding for our customers with a lower tota

Hewlett Packard Enterprise Launches Gaia-X Solutions to Accelerate Data Value Creation18.5.2021 13:00:00 CEST | Press release

Hewlett Packard Enterprise (NYSE: HPE) today announced solutions to help organizations advance data monetization by tapping into Gaia-X, an emerging federated data infrastructure supported by more than 300 organizations in Europe and globally. The HPE Solution Framework for Gaia-X was designed for companies, service providers and public organizations that want to get ready to participate in Gaia-X. It supports virtually all capabilities that are required to both provide and consume data and services in a decentralized, federated environment. As a result, organizations can advance their ability to create value from data, tap into huge distributed data pools, and strengthen their sovereignty over their data-driven business model. The framework is based on a reference architecture, leveraging key components of HPE’s software portfolio, third-party software, and the Cloud28+ business platform, a marketplace for the monetization of data and services. Individual solution components and entir

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom